JD Health (6618) Stock Price, Fundamentals & Analysis

What 6618 does

JD Health (6618) is a stock listed on the Hong Kong Stock Exchange in the Healthcare sector, specifically the Pharmaceutical Retailers industry. Headquartered in Beijing, China, the company operates an online healthcare platform in the People's Republic of China. Its services include online medical consultation, hospital or doctor referrals, health check-ups, genetic testing, and beauty care, as well as internet healthcare, health management, and intelligent healthcare solutions. The company also provides home care services such as wound care, blood tests, post-operative care, and medical escort, alongside online medical insurance payments and smart healthcare digital solutions. In addition, JD Health offers online marketing services to advertisers, online shopping and hospital services, smart monitoring and respiratory therapy devices, senior-oriented medical devices, home medical device set-up and support, and rapid testing products.

Key numbers explained

• The current price is 35.08 HKD, representing a -2.01% change today.
• The trailing P/E ratio of 15.5 compares the stock price to the last 12 months of earnings; a lower figure can suggest relative value, while a higher one may reflect growth expectations.
• The forward P/E ratio of 11.9 uses expected future earnings, offering a look at how the market prices the company's upcoming profitability.
• The dividend yield is 0%, meaning the company currently pays no cash dividend to shareholders.
• The beta of 1.18 indicates the stock's historical volatility relative to the broader market; a beta above 1 suggests it tends to move more than the market.
• The 52-week price range of 31.84 – 71.7 shows the lowest and highest traded prices over the past year, with the current price near the lower end of that span.
• The price-to-book ratio of 1.56 compares the market price to the company's book value per share, a common measure of whether a stock trades at a premium or discount to its net assets.
• The debt-to-equity ratio of 1.4 expresses the company's financial leverage, indicating the proportion of debt used relative to shareholder equity.

What to watch

The stock's performance is influenced by general factors common to healthcare and pharmaceutical retail companies. Regulatory changes in China's healthcare sector, shifts in consumer demand for online medical services, and competitive dynamics with peers such as Alibaba Health (0241) and Sinopharm Group (1099) can affect the business. Broader market movements on the Hong Kong Stock Exchange and sector trends, including those seen among peers like Hansoh Pharmaceutical Group (3692) and WuXi AppTec (2359), are also relevant. Investors often monitor upcoming earnings releases, with the next one scheduled for 13 aug. 2026.